• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cyclacel Pharmaceuticals Inc. - Product Pipeline Review - H2 2011 Product Image

Cyclacel Pharmaceuticals Inc. - Product Pipeline Review - H2 2011

  • Published: November 2011
  • Region: Global
  • 101 pages
  • Global Markets Direct

Cyclacel Pharmaceuticals Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Cyclacel Pharmaceuticals Inc. - Product Pipeline Review - H2 2011” provides data on the Cyclacel Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cyclacel Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cyclacel Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cyclacel Pharmaceuticals Inc. - Brief Cyclacel Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cyclacel Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy READ MORE >



List of Tables
List of Figures
Cyclacel Pharmaceuticals Inc. Snapshot
Cyclacel Pharmaceuticals Inc. Overview
Key Information
Key Facts
Cyclacel Pharmaceuticals Inc. – Research and Development Overview
Key Therapeutic Areas
Cyclacel Pharmaceuticals Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cyclacel Pharmaceuticals Inc. – Pipeline Products Glance
Cyclacel Pharmaceuticals Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cyclacel Pharmaceuticals Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cyclacel Pharmaceuticals Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Cyclacel Pharmaceuticals Inc. – Drug Profiles
CDK Inhibitors Program
Product Description
Mechanism of Action
R&D Progress
Cell Cycle Inhibitors Program
Product Description
Mechanism of Action
R&D Progress
CYC116
Product Description
Mechanism of Action
R&D Progress
GSK-3 Inhibitors Program
Product Description
Mechanism of Action
R&D Progress
PLK1 Inhibitor Program
Product Description
Mechanism of Action
R&D Progress
Sapacitabine
Product Description
Mechanism of Action
R&D Progress
Sapacitabine + Decitabine
Product Description
Mechanism of Action
R&D Progress
Sapacitabine + Seliciclib
Product Description
Mechanism of Action
R&D Progress
Cyclacel Pharmaceuticals Inc. – Pipeline Analysis
Cyclacel Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class
Cyclacel Pharmaceuticals Inc. - Pipeline Products By Target
Cyclacel Pharmaceuticals Inc. – Pipeline Products by Route of Administration
Cyclacel Pharmaceuticals Inc. – Pipeline Products by Molecule Type
Cyclacel Pharmaceuticals Inc. – Recent Pipeline Updates
Cyclacel Pharmaceuticals Inc. - Dormant Projects
Cyclacel Pharmaceuticals Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Cell Cycle Inhibitors Program
Cyclin Binding Groove Inhibitors
Hdm2 Inhibitor Program
Cyclacel Pharmaceuticals Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 31, 2007: Cyclacel Initates Phase 2 Sapacitabine Trial In Elderly AML Patients
Nov 30, 2009: Cyclacel' Sapacitabine Phase 1 Data Published In Acute Leukemia And Myelodysplastic Syndromes
Aug 30, 2011: Cyclacel Commences Investigator-Initiated Phase II Trial Of Sapacitabine In Patients With CLL Or SLL Hematological Malignancies And 11q22-23 deletion
Apr 30, 2007: Cyclacel Pharmaceuticals Begins Phase II Study Of Oral Sapacitabine In Patients With Advanced Cutaneous T-cell Lymphoma
Jun 29, 2007: Cyclacel Pharmaceuticals Initiates Phase I study Of CYC116 In patients With Advanced Solid Tumors
Jun 29, 2006: Cyclacel Begins A Phase IIb Randomized Trial Of Seliciclib For Previously Treated Non-Small Cell Lung Cancer
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting
May 29, 2009: Cyclacel Reports Phase 2 Sapacitabine Data In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes At 2009 Asco Annual Meeting
May 29, 2008: Vall d’Hebron University Hospital And Cyclacel Announces To Initiate Phase 1 Combination Study Of Seliciclib And Tarceva
Nov 28, 2006: Cyclacel Reports Interim Phase I Data For Sapacitabine
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies
May 27, 2008: Cyclacel’s Sapacitabine Receives Orphan Designation For AML & MDS From EU Regulators
May 24, 2007: Cyclacel Pharmaceuticals Announces To Report Sapacitabine Phase I Study Results At The American Society of Clinical Oncology Annual Meeting
Dec 21, 2010: Cyclacel Announces Topline Results From APPRAISE Phase IIb Study Of Seliciclib
Oct 21, 2008: Cyclacel Announces To Present Preclinical Data Showing Synergy Of Combination Of Sapacitabine With Histone Deacetylating Agents
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR
Feb 20, 2006: BCY LifeSciences and Pipex Therapeutics Announce Proposed Business Combination Structure
Nov 19, 2010: Cyclacel To Present Sapacitabine Phase II And Myelodysplastic Syndromes Data At ASH Annual Meeting
May 19, 2011: Cyclacel To Report New Sapacitabine Clinical Data At ASCO 2011 Annual Meeting
Apr 17, 2007: Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data At AACR
Feb 17, 2011: Targeting CDK2/cyclin E With CYC065 Overcomes Herceptin Resistance In HER2 Positive Breast Cancer
Dec 15, 2009: Cyclacel Pharmaceuticals To Meet U.S. Food and Drug Administration (FDA) For Phase 3 Study Design Of Sapacitabine
Jun 15, 2006: Cyclacel Begins Phase I Pharmacologic Study Of Oral Sapacitabine In Patients With Advanced Leukemias
May 15, 2005: Cyclacel Reports Interim Seliciclib Phase IIa Data At 2005 ASCO
Sep 14, 2001: BCY Initiates Phase I Trial Of DCF 987
Jul 14, 2008: Cyclacel Publishes Study Of Seliciclib Synergy With Tarceva And Herceptin In Journal Clinical Cancer Research
Dec 13, 2006: Cyclacel Submits IND Of CYC116 An Aurora Kinase And VEGRF2 Inhibitor To Treat Cancer
Oct 13, 2011: Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue SEAMLESS Phase III Trial Of Sapacitabine
Sep 13, 2010: Cyclacel Reaches Agreement With FDA On SPA For Phase III Trial Of Sapacitabine In Acute Myeloid Leukemia
Jan 13, 2009: Cyclacel Begins Phase 2 Study Of Oral Sapacitabine In Patients With Previously Treated Non-Small Cell Lung Cancer
Sep 12, 2008: Cyclacel Expands Phase 2 Sapacitabine Trial In Elderly AML To Include Patients With MDS
Jun 12, 2007: Cyclacel Pharmaceuticals Announces To Host Conference Call To Review Sapacitabine Phase I Hematology Data
Apr 11, 2007: Cyclacel Pharmaceuticals Announces To present Preclinical Data On Sapacitabine And Seliciclib At AACR
Apr 11, 2007: Cyclacel Pharmaceuticals To Present Preclinical Data On Sapacitabine And Seliciclib At AACR
Jan 11, 2011: Cyclacel Begins Phase III SEAMLESS Trial Of Sapacitabine In Acute Myeloid Leukemia
Nov 10, 2010: Cyclacel Announces Publication Of Preclinical Data Of Sapacitabine With Targeted Agents For Treatment Of Cancer
Nov 10, 2006: Cyclacel Reports Phase I Sapacitabine Study Results At 18th EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Meeting
Oct 09, 2008: Cyclacel Announces Completion Of Enrollment In Phase 2 Trial Of Sapacitabine In Elderly AML
Dec 08, 2007: Cyclacel Reports Updated Phase I Sapacitabine Data At 2007 ASH Meeting
Jun 08, 2009: Cyclacel's Sapacitabine Has Anti-Cancer Activity In Combination With Targeted Agents & Other Nucleoside Analogs
Jun 08, 2009: Cyclacel's Sapacitabine Has Anti-Cancer Activity In Combination With Targeted Agents & Other Nucleoside Analogs
Dec 07, 2004: Cyclacel's Seliciclib (CYC202) Shown To Kill Multiple Myeloma Cells
Jun 07, 2010: Cyclacel Reports Interim Phase II Sapacitabine Data In Myelodysplastic Syndromes At 2010 ASCO Annual Meeting
Feb 06, 2009: Cyclacel Pharmaceuticals Advances Oral Sapacitabine Pivotal Trial Plan In Hematological Malignancies
Dec 05, 2010: Cyclacel’s CYC065 Demonstrates Activity In Multiple Myeloma In Preclinical Studies
Dec 05, 2009: Cyclacel Announces Phase II Study Results Of Sapacitabine For Acute Myeloid Leukemia And Myelodysplastic Syndromes At 2009 ASH Annual Meeting
Dec 05, 2007: Cyclacel Pharmaceuticals Announces Sapacitabine Poster Presentation At Upcoming American Society Of Hematology Meeting
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer
Feb 05, 2007: Cyclacel Announces Development Plan For Its Seliciclib CDK inhibitor To Treat Nasopharyngeal Cancer
Dec 04, 2010: Cyclacel Reports Phase II Survival Data With Sapacitabine In Myelodysplastic Syndromes At ASH Annual Meeting
Jun 02, 2007: Cyclacel Reports Phase I Sapacitabine Data In Patients With Advanced Leukemias And Myelodysplastic Syndromes At 2007 ASCO
Jul 01, 2010: Cyclacel Receives FDA Orphan Drug Designation For Sapacitabine In Acute Myeloid Leukemia And Myelodysplastic Syndromes
Mar 01, 2005: BCY LifeSciences Signs Licencing Agreement With ALIGN Pharmaceuticals For DCF 987
Financial Deals Landscape
Cyclacel Pharmaceuticals Inc., Deals Summary
Cyclacel Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Cyclacel Pharmaceutical Secures $8.8 Million In Financing
Cyclacel Raises $39 Million In Series D Financing
Partnerships
Cyclacel Enters Into Co-Development Agreement With ALTANA Pharma
Licensing Agreements
Cyclacel Pharmaceuticals Amends Its Licensing Agreement With Daiichi Sankyo For Sapacitabine
Sinclair Pharma Enters Into Licensing Agreement With Align Pharmaceuticals
BCY LifeSciences Enters Into Licensing Agreement With ALIGN Pharmaceuticals
Corgentech Enters Into Licensing Agreement With Cyclacel
Equity Offering
Cyclacel Pharmaceuticals Completes An Underwritten Public Offering Of $10.4 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $15 Million
Cyclacel Completes Private Placement Of $5.9 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $7 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $3.4 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $36 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $45 Million
Acquisition
Cyclacel Pharmaceuticals Acquires ALIGN Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Cyclacel Pharmaceuticals Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline by Stage of Development, H2 2011
Cyclacel Pharmaceuticals Inc. – Monotherapy Products in Pipeline, H2 2011
Cyclacel Pharmaceuticals Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Cyclacel Pharmaceuticals Inc. – Phase III, H2 2011
Cyclacel Pharmaceuticals Inc. - Phase II, H2 2011
Cyclacel Pharmaceuticals Inc. - Phase I, H2 2011
Cyclacel Pharmaceuticals Inc. - Pipeline By Therapeutic Class, H2 2011
Cyclacel Pharmaceuticals Inc. - Pipeline By Target, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline By Route of Administration, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline By Molecule Type, H2 2011
Cyclacel Pharmaceuticals Inc. – Recent Pipeline Updates, H2 2011
Cyclacel Pharmaceuticals Inc. - Dormant Developmental Projects, 2010
Cyclacel Pharmaceuticals Inc. - Discontinued Pipeline Products, 2010
Cyclacel Pharmaceuticals Inc., Other Locations
Cyclacel Pharmaceuticals Inc., Subsidiaries
Cyclacel Pharmaceuticals Inc., Deals Summary
Cyclacel Pharmaceutical Secures $8.8 Million In Financing
Cyclacel Raises $39 Million In Series D Financing
Cyclacel Enters Into Co-Development Agreement With ALTANA Pharma
Cyclacel Pharmaceuticals Amends Its Licensing Agreement With Daiichi Sankyo For Sapacitabine
Sinclair Pharma Enters Into Licensing Agreement With Align Pharmaceuticals
BCY LifeSciences Enters Into Licensing Agreement With ALIGN Pharmaceuticals
Corgentech Enters Into Licensing Agreement With Cyclacel
Cyclacel Pharmaceuticals Completes An Underwritten Public Offering Of $10.4 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $15 Million
Cyclacel Completes Private Placement Of $5.9 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $7 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $3.4 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $36 Million
Cyclacel Pharmaceuticals Completes Private Placement Of $45 Million
Cyclacel Pharmaceuticals Acquires ALIGN Pharmaceuticals

List of Figures
Cyclacel Pharmaceuticals Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline by Stage of Development, H2 2011
Cyclacel Pharmaceuticals Inc. – Monotherapy Products in Pipeline, H2 2011
Cyclacel Pharmaceuticals Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline By Therapeutic Class, H2 2011
Cyclacel Pharmaceuticals Inc. - Pipeline By Target, H2 2011
Cyclacel Pharmaceuticals Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS